Valeant
Allergan and Valeant trade blows as shareholder meeting looms
November 6, 2014Sales and Marketing Actavis, Allergan, Forest, Valeant, merger, warner
Allergan’s efforts to block a key supporter of Valeant’s hostile takeover bid from voting at next month’s special shareholder meeting …
Valeant goes hostile over Allergan hunt
June 19, 2014Sales and Marketing Allergan, Botox, Valeant, hostile, takeover
Valeant Pharmaceuticals has turned hostile in its bid to acquire Botox maker Allergan by employing strong-arm tactics in an attempt …
Allergan rejects Valeant – again
June 11, 2014Research and Development, Sales and Marketing Allergan, Botox, Valeant, pershing, pharma
Allergan and Valeant Pharmaceuticals International are continuing their stately dance around one another – and in the latest move the …
Valeant ‘substantially undervalues’ Allergan
May 13, 2014Sales and Marketing Allergan, Botox, Pfizer, Valeant, buyout, merger
Allergan’s board has issued a defiant, unanimous rejection of the multi-billion dollar takeover offer made public by Valeant last month. In …
Valeant makes $45.7 billion Allergan offer
April 23, 2014Sales and Marketing Allergan, Botox, GSK, Novartis, Pfizer, Valeant, merger, pershing
In the latest proposal in a flurry of merger and acquisition activity in the pharma sector, Valeant Pharmaceuticals International wants …
Valeant to buy B+L for $8.7 billion
May 29, 2013Sales and Marketing B+L, Valeant
Canadian firm Valeant Pharmaceuticals International is to buy Bausch + Lomb in an $8.7 billion deal which will see the …
FDA rejects Valeant’s efinaconazole on packaging grounds
May 29, 2013Manufacturing and Production FDA, Valeant
Valeant Pharmaceuticals has had its application to market antifungal candidate efinaconazole turned down by the FDA because of issues related …
Valeant shuts plant in Brazil, second to follow
January 8, 2013Manufacturing and Production Brazil, Medicis, Valeant
Canadian firm Valeant Pharmaceuticals has closed down one of its facilities in Brazil and will shutter a second in the …
Valeant to buy dermatogy firm Medicis
September 4, 2012Sales and Marketing Valeant
Speciality pharma company Valeant is to acquire dermatology-focused Medicis for $2.6 billion.Medicis’ portfolio includes ‘cosmaceutical’ prescription brands such as Solodyn, …
Sanofi sells dermatology unit for $425m
July 11, 2011Manufacturing and Production, Sales and Marketing Canada, Dermik, Sanofi, Valeant, dermatology
Sanofi has sold its Canadian dermatology unit Dermik for $425 million in order to concentrate on key growth areas like …
GSK’s epilepsy treatment Potiga wins US approval
June 13, 2011Sales and Marketing GSK, Potiga, Trobalt, Valeant, epilepsy
The FDA has approved GlaxoSmithKline and Valeant’s epilepsy treatment Potiga, but the drug will require further review before it can …
Cephalon accepts Teva’s $6.8 billion white knight bid
May 3, 2011Research and Development, Sales and Marketing Cephalon, Teva, Valeant, generics
Generics giant Teva has acquired Cephalon for $6.8 billion and says the deal will make it a leading specialty pharmaceutical …
GSK and Valeant’s epilepsy treatment approved
April 8, 2011Sales and Marketing GSK, Trobalt, Valeant, epilepsy
The European Commission has granted marketing authorisation for Trobalt, the new epilepsy drug from GSK and Valeant. Trobalt (retigabine) has …
Valeant makes $5.7 billion hostile bid for Cephalon
March 31, 2011Research and Development, Sales and Marketing Cephalon, Valeant
Valeant has made a hostile bid for Cephalon, but analysts believe its offer is too low for the deal to …
Manufacturing news in brief
April 6, 2010Manufacturing and Production NIB, Valeant, Warner Chilcott, baxter
This week’s round-up of recent developments in the pharmaceutical manufacturing arena sees a new facility build for Ireland’s HKPB and …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
